

Development of complement C4d X CD3 BiTE

Seoul National University



ONCOLOGY	Hit
Product Type	Immunoglobulin Product (Bispecific antibody)
Indication	Lymphoma(MeSH term)
Target	Complement C4d
MoA(Mechanism of Action)	<p>CDC is triggered when rituximab binds to cells → After complement pathway activates, c4d is deposited on cells → BiTE binds to cell surface via deposited C4d → T cell activation via binding CD3 → Targeted therapy for cancer</p>
Competitiveness	<ul style="list-style-type: none"> Existing BiTE or those under clinical development have limitations in terms of high recurrence rate resulting from antigenic heterogeneity in cancer tissues and the loss of antigen during the treatment process. By developing BiTE based on a novel mechanism to overcome such constraint, it is expected that a strong, synergetic anticancer effect will be achieved through combined treatment with most antibody-induced complement dependent cytotoxicity (CDC) regardless of the specific cancer antigen
Development Stage	Hit
Route of Administration	Parental-Intravenous